Wall Street brokerages expect that Endocyte, Inc. (NASDAQ:ECYT) will announce earnings of ($0.25) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Endocyte’s earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.27). Endocyte also reported earnings per share of ($0.25) during the same quarter last year. The company is scheduled to issue its next quarterly earnings report on Thursday, August 3rd.
According to Zacks, analysts expect that Endocyte will report full-year earnings of ($0.88) per share for the current fiscal year, with EPS estimates ranging from ($0.93) to ($0.84). For the next financial year, analysts expect that the business will report earnings of ($0.75) per share, with EPS estimates ranging from ($0.76) to ($0.73). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Endocyte.
Endocyte (NASDAQ:ECYT) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. Endocyte had a negative return on equity of 29.67% and a negative net margin of 59,808.57%. The company had revenue of $0.01 million for the quarter. During the same period last year, the company earned ($0.24) EPS. The business’s revenue was up .0% compared to the same quarter last year.
Several research analysts have issued reports on the stock. Wedbush lowered shares of Endocyte from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $8.00 to $2.00 in a research report on Monday, June 5th. Zacks Investment Research raised shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Friday, May 19th. Cowen and Company lowered shares of Endocyte from an “outperform” rating to a “market perform” rating in a research note on Friday, June 2nd. Finally, ValuEngine lowered shares of Endocyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $3.58.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its position in shares of Endocyte by 284.4% in the first quarter. Renaissance Technologies LLC now owns 192,561 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 142,461 shares during the period. Algert Global LLC bought a new stake in Endocyte during the first quarter worth about $345,000. Parametric Portfolio Associates LLC boosted its stake in Endocyte by 57.8% in the first quarter. Parametric Portfolio Associates LLC now owns 162,329 shares of the biopharmaceutical company’s stock worth $417,000 after buying an additional 59,454 shares in the last quarter. Two Sigma Investments LP bought a new stake in Endocyte during the fourth quarter worth about $140,000. Finally, Ameriprise Financial Inc. boosted its stake in Endocyte by 26.7% in the first quarter. Ameriprise Financial Inc. now owns 133,270 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 28,110 shares in the last quarter. 33.02% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “-$0.25 Earnings Per Share Expected for Endocyte, Inc. (ECYT) This Quarter” was originally published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.baseball-news-blog.com/2017/08/19/0-25-earnings-per-share-expected-for-endocyte-inc-ecyt-this-quarter-updated-updated-updated.html.
Endocyte (NASDAQ:ECYT) traded up 0.70% during trading on Monday, hitting $1.44. The stock had a trading volume of 64,039 shares. Endocyte has a one year low of $1.36 and a one year high of $3.49. The company’s market cap is $61.16 million. The firm has a 50 day moving average of $1.56 and a 200-day moving average of $2.16.
Endocyte Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.